NAMUSCLA 167 mg, capsules 100 capsules
Active ingredients: (RS)-mexiletine hydrochloride, MEXILÉTINE
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule100 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- NAMUSCLA 167 mg, gélules
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) PVC PVDC aluminium de 100 gélule(s)
- Marketing authorisation holder
- LUPIN EUROPE (ALLEMAGNE)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 14 Jun 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67638864CIP73017214CIP133400930172148Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE DE MEXILÉTINEgélule | — | SA |
| MEXILÉTINEgélule | 166,62 mg · une gélule | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.